title: [BRONCHOPULMONARY DYSPLASIA--WHAT DO WE KNOW TODAY?].
abstract: The survival of great number of extremely premature newborn babies is associated with increased risk of damage of the newborn lung and development of chronic lung disease/Broncopulmonary dysplasia. The lower the gestational age and weight, the greater the frequency of BPD. The disease leads to impairment of the normal alveolization and vascularization of the premature lung. There are new theories for the pathogenesis of BPD and new staging of the disease. These changes lead to new therapeutic strategies.
authors: P
authors: P
authors: Radulova
authors: L
authors: L
authors: Vakrilova
authors: B
authors: B
authors: Slancheva
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001724:Birth Weight; D001993:Bronchodilator Agents / Q000627:therapeutic use; D001997:Bronchopulmonary Dysplasia / Q000453:epidemiology* / Q000473:pathology* / Q000628:therapy; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000473:pathology*; D020105:Milrinone / Q000627:therapeutic use; D009569:Nitric Oxide / Q000627:therapeutic use; D011247:Pregnancy; D000068677:Sildenafil Citrate / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D001993:Bronchodilator Agents; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D020105:Milrinone